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AbstrAct:
Acute myeloid leukemia (AML) comprises a heterogeneous group of clonal disorders 
of hematopoietic progenitors. We previously showed that heme oxygenase-1 (HO-
1/Hsp32) underlies resistance of AML to TNF-induced apoptosis.  Here we show for 
the first time that the modulatory protein, FLICE-inhibitory protein (FLIP) indirectly 
regulates induction of HO-1 in response to TNF in human AML blasts, but not non-
cancerous control cells.  In AML cells, TNF-induced FLIP expression was an NF-κB-
dependent event, and silencing of FLIP isoforms (FLIPL, FLIPS and FLIPR) induced 
pro-apoptotic responses to TNF, with FLIPL knock-down providing the greatest 
apoptotic switch.  However, FLIPL knock-down consequently increased expression 
of HO-1; a response that occurred in AML (but not non-cancerous) cells to protect 
a proportion of them from apoptotic death. Our results show that increases in HO-1 
induced an apoptotic-resistant form in AML cells in the absence of FLIPL. This is the 
first time that FLIPL has been shown to regulate the expression of HO-1. These data 
reveal unique regulatory networks in cancerous AML cells whereby FLIP regulation 
of HO-1 provides AML cells with secondary anti-apoptotic protection against extrinsic 
factors (eg TNF/chemotherapies) that try to switch on death signals in these highly 
death-resistant cells. Future AML therapies should target these mechanisms.
IntroductIon
Acute myeloid leukemia (AML) is a malignancy 
of the myeloid progenitors, characterized by the rapid 
growth of abnormal myeloid cells that accumulate in the 
bone marrow and blood. AML is the most common acute 
leukemia affecting adults, and its incidence increases with 
age with 75% of patients diagnosed after the age of 60 [1]. 
Furthermore, with current intensive therapeutic strategies 
generally limited to a minority of younger, fitter patients, 
there is a significant unmet need for better tolerated anti-
AML therapy [2]. Therefore understanding the processes 
that protect these complicated cells from undergoing 
apoptosis in response to endogenous signals is an essential 
step to developing new improved anti-AML therapy. 
Apoptosis is an essential part of mechanisms that 
maintain normal cellular homeostasis. Deregulation of 
the apoptosis machinery and evasion of apoptosis is a 
mechanism of most human malignancies, including AML 
[3,4]. Most systemic anti-cancer therapies (SACT) act by 
the induction of apoptosis, therefore, evasion of apoptosis 
is  mainly  responsible  for  the  insufficiency  of  current 
therapies. It is well documented that malignant cells can 
die of apoptosis primarily through the extrinsic death 
receptor-induced  pathway  [5],  the  activation  of  which 
involves ligation of a death ligand with trimerization 
of death receptors, leading to the formation of the 
death-inducing  signaling  complex  (DISC)  followed  by 
the  activating  cleavage  of  caspase-8  in  the  DISC  [6]. 
Apoptosis  mediated  via  DISC  is  regulated  by  cellular Oncotarget 2010; 1:  359 - 366 360 www.impactjournals.com/oncotarget
Fas-associated  protein  with  death  domain-like  IL-1β-
converting enzyme inhibitory protein (FLIP)[7]. 
FLIP mediated regulation of the DISC is through 
the modulation of activation of procaspase-8 and thereby 
prevents induction of apoptosis mediated by death receptors 
[8]. Inducible control of FLIP expression is thought to be 
controlled by the transcription factor nuclear factor-κB 
(NF-κB) however we have shown that other transcription 
binding sites do exist in the FLIP promoter [9]. The human 
FLIP gene, with an estimated size of ~48000 base pairs, 
consists of at least 14 exons. It has been described that at 
least 11 different isoforms of cellular FLIP are transcribed 
at the mRNA level, generating different splice variants 
with only three of these splice variants having been 
detectable as protein (FLIPL, FLIPS and FLIPR)[9]. The 
FLIP isoforms have been shown to have conflicting roles 
in the regulation of apoptosis at the DISC. While FLIPS 
and FLIPR have been shown to have a clear anti-apoptotic 
function, the role of FLIPL in regulating apoptosis has 
been found to be quite controversial [10,11]. Most reports 
describe FLIPL as an anti-apoptotic molecule that blocks 
caspase activation, whereas, others suggest that FLIPL 
catalyzes caspase-8 processing at the DISC and therefore 
has a pro-apoptotic function. 
We have previously shown that in the human AML 
cell line THP-1, FLIPL is induced in a NF-κB-dependent 
response [3]. In the same study we showed that FLIPL had 
only a limited role in regulating apoptosis in AML cells 
in response to TNF-mediated death responses. Here we 
demonstrate a novel pathway involving FLIPL negatively 
regulating the expression of heme oxygenase-1 (HO-1), 
whose role in chemoresistance, both in AML and other 
cancers, is well established.
Figure 1: differential regulation of FLIP isoform expression by tnF in human AML. (A) AML samples, AML cell lines 
and non-malignant control cells were treated with TNF (10 ng/ml) for up to 24 h. Total RNA was extracted, reverse transcribed and relative 
expression of FLIPL (triangles), FLIPS (squares) and FLIPR (diamonds) mRNA expression was measured by real-time PCR. Data represent the 
means ± SEM, from three separate experiments. (B) THP-1 cells were treated without (open symbols) or with BAY 11-7082 (10 μM, closed 
symbols) for 24 h prior to treatment with 10 ng/ml TNF for the indicated times. Total RNA was extracted, reverse transcribed and relative 
expression of FLIPL, FLIPS and FLIPR mRNA expression was measured by real-time PCR. (C) Whole cell Western blot analyses performed 
for FLIPL, FLIPS and FLIPR on THP-1 cells in response to treatments with BAY 11-7082 (10 μM) 1 h prior to 10 ng/ml TNF for the indicated 
times. β-actin levels were used as loading controls to compare equal loading.
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Figure 2: differential effects of silencing FLIP isoforms on tnF apoptotic responses. (A) Human monocytes and THP-1 cells 
were transfected with 30 nM of either control siRNA or FLIPL, FLIPS or FLIPR-specific siRNA for 24 h. Total RNA was extracted, reverse 
transcribed and relative mRNA expression of the indicated FLIPL, FLIPS or FLIPR isoform was measured by real-time PCR. Data represent 
means ± SEM, from three independent experiments. (B) Human monocytes and THP-1 cells were transfected with 30 nM of either control 
siRNA or FLIPL, FLIPS or FLIPR-specific siRNA for 24 h before treatment with 10 ng/ml TNF for 24 h. Apoptosis was measured using annexin 
V and propidium iodide (PI) staining followed by flow cytometry analysis. 
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resuLts
FLIP isoform expression in human AML in 
response to tnF
Previously we have shown that the FLIP isoform, 
FLIPL, is induced in AML cell line THP-1 and HL60, in 
response to TNF in a NF-κB-dependent mechanism [3]. 
Others have shown that cFLIP can protect cells from TNF 
induced apoptosis [12]. Moreover the function of the three 
recognised FLIP isoforms (FLIPL FLIPS and FLIPR) has 
not been wholly established in human AML. Therefore, 
we wanted to fully elucidate the induction of FLIP 
isoforms (FLIPL FLIPS and FLIPR) in response to TNF 
in human AML patient samples, AML cell lines and non-
malignant control cells. Cells were treated with TNF for 
various time points Figure 1A shows the mRNA induction 
of FLIP isoforms in response to TNF in human AML cells. 
This shows that FLIPL, FLIPS and FLIPR are all induced by 
TNF in a time dependent fashion, with all FLIP isoforms 
mRNAs  being  significantly  raised  from  at  least  4  h 
treatment with TNF. FLIPL has the greatest induction in all 
cells tested suggesting that this protein may have the most 
influence on apoptotic pathways. Figure 1B confirms that 
the induction of FLIPL and FLIPS, but not FLIPR by TNF 
is a NF-κB-dependent response. The slight but significant 
mRNA induction of FLIPR by TNF is not controlled by 
NF-κB. Figure 1C shows the protein induction of these 
proteins in THP-1 cells confirming that NF-κB regulates 
this response. One interesting observation is that we could 
not detect the protein for FLIPR, thus suggesting that 
mRNA is not processed into protein or the protein level of 
FLIPR is lower than the detectable concentration for this 
assay.
sirnA silencing of FLIP isoforms induced 
differential apoptotic responses to tnF
To  understand  the  significance  of  TNF-induced 
FLIPL, FLIPS and FLIPR expression in human AML we 
Gene Id Forward reverse
GAPdH 5’-AccAGcctcAAGAtcAtcAGc-3’ 5’-tGctAAGcAGttGGtGGtGc-3’
Ho-1 5’-AtGGcctccctGtAccAcAtc-3’ 5’-tGttGcGctcAAtctcctcct-3’
FLIPL 5’-GttcAAGGAGcAGGGAcAAG-3’ 5’-tcccAttAtGGAGcctGAAG-3’
FLIPs 5’-GttcAAGGAGcAGGGAcAAG-3’ 5’-AtcAGGAcAAtGGGcAtAGG-3’
FLIPr 5’-GttcAAGGAGcAGGGAcAAG-3’ 5’-ctttcAtGctGGGAttccAtA-3’
Figure 3: the effect on Ho-1 expression of silencing FLIPL isoform, alone and in response to tnF. (A) AML samples, AML 
cell lines and non-malignant control cells were transfected with 30 nM of either control siRNA or FLIPL, FLIPS or FLIPR-specific siRNA for 48 
h, then HO-1 RNA was analysed using real-time PCR. Data represent means ± SEM, from three separate experiments. (B) Human monocytes 
and THP-1 cells were transfected with 30 nM of FLIPL-specific siRNA for 30 h, followed by Western blot analysis for HO-1 protein expression. 
β-actin levels were also used to compare equal protein loading among samples.
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used siRNA to target knockdown of these modulators. 
Figure 2A shows that we can effectively and specifically 
knockdown mRNA levels of FLIPL, FLIPS and FLIPR in 
human AML cells. When we knocked down FLIPL, FLIPS 
and FLIPR expression in AML cell line THP-1 and human 
monocytes (Figure 2B) we showed there to no difference 
in apoptotic response between control knockdown and 
FLIPL or FLIPS or FLIPR  knockdown  in  THP-1  cells, 
however we did see a significant increase in monocyte 
apoptosis in FLIPL-targeted  cells.  When  we  activated 
transfected cells using TNF, we found that cells targeted 
with FLIPL knockdown, but not FLIPS and FLIPR, were 
susceptible to apoptosis. Nevertheless, in this assay, the 
cells treated with FLIPL knockdown in combination with 
TNF showed only 44% apoptosis, thus suggesting that 
some other mechanism is controlling apoptotic responses 
in the remaining 56% of live cells. However, these findings 
do suggest that FLIPL but not FLIPS or FLIPR can partially 
regulate TNF-induced apoptosis in human AML cells
FLIPL-targeted  knockdown  induced  HO-1 
expression.
Since we have shown that constitutive expression of 
HO-1 is regulated by NF-κB in human AML and that FLIP 
is known to play a role in controlling NF-κB induction 
we wanted to determine if FLIP knockdown could induce 
HO-1 expression [13,14]. We used siRNA to knockdown 
the FLIP isoform expression in two AML samples 
(AML303 and AML306), as well as in the AML cell 
line THP-1 and non-malignant control cells. Figure 3A 
shows that when we knockdown FLIPL protein, we induce 
expression  of  cytoprotective  genes  HO-1  in AML303, 
AML306  and THP-1,  but  not  control  cells.  Figure  3B 
confirms these findings at the protein level. Taken together 
these data suggest that under normal basal conditions in 
AML, FLIPL normally regulates the expression of HO-1 
in cancerous cells only. 
Enhanced apoptotic responses to TNF by silencing 
FLIPL in combination with HO-1.
Finally we wanted to determine if silencing FLIPL 
and HO-1 in combination could induce further apoptosis 
in AML cells in response to TNF. When we knocked down 
FLIPL and HO-1 in AML cell line THP-1 (Figure 4) we 
showed that TNF induced a significantly greater apoptotic 
response in these AML cells when compared to cells 
with separate knockdown of either FLIPL or HO-1 alone. 
Preventing the function of both FLIPL and HO-1 together, 
allows the vast majority (73%) of AML cells to become 
sensitive to TNF-induced death, compared to only 6% of 
the same cells dying in the absence of TNF. Interestingly, 
knockdown of HO-1 alone allowed only 15% of AML 
cells to be sensitive towards TNF-induced death. These 
findings  suggest  that  together  FLIPL  and  HO-1  protect 
AML cells from TNF-induced apoptosis and both need to 
be targeted for effective AML therapy.
dIscussIon
Understanding host responses that modulate 
apoptosis in human AML is key to developing new 
therapeutic strategies to reduce the mortality associated 
with this complex disease. The present study demonstrates 
that FLIPL can regulate the expression of HO-1, and that 
Figure 4: silencing FLIPL in combination with Ho-1 allows enhanced apoptotic responses of tnF. (A) THP-1 cells were 
transfected with 30 nM of either control siRNA or FLIPL-specific siRNA in combination with HO-1-specific siRNA for 24 h and then treated 
with 10 ng/ml TNF for 24 h. Cellular apoptosis was measured by annexin V and propidium iodide staining followed by flow cytometry analysis. 
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targeting knockdown of both molecules using siRNA 
improves apoptosis in response to TNF treatment.   
Most research to date regarding the importance of FLIP 
in regulating cell survival has focused on its role in 
preventing the formation of the DISC. This is the first time 
FLIP has been shown to regulate HO-1 gene induction in 
human cells, moreover, targeting both HO-1 and FLIP in 
combination could markedly improve survival rates in 
human AML.
The regulation of apoptosis in human AML is the 
focus  of  our  research. We  have  previously  shown  that 
inhibiting HO-1 and NF-κB in combination allows AML 
cells to undergo apoptosis, thus suggesting that both these 
pathways are needed for the survival of these malignant 
cells  [13].  HO-1  protects  AML  cells  from  apoptosis 
through its antioxidant metabolites bilirubin and carbon 
monoxide, which sequester free radicals associated with 
modern chemotherapies [15]. FLIPL which is induced in 
AML in response to TNF in a NF-κB-dependent manner, 
is able to inhibit apoptosis by modulating activation of 
procaspase-8  and  thereby  inhibiting  formation  of  the 
DISC [5]. We found in this study that by removing the 
induction of FLIPL but not FLIPS or FLIPR, induced the 
expression of the cytoprotective protein HO-1.
Expression of HO-1 is usually increased in human 
cancer cells, however we have recently shown that in 
human AML cells HO-1 expression is significantly lower 
when compared with nonmalignant control cells [13]. 
Further analysis found that the NF-κB subunits p50 and 
p65  negatively  regulated  the  expression  of  this  HO-1 
mRNA by binding to a putative κB-binding site located 
in the HO-1 gene upstream of the antioxidant response 
element (ARE) which subsequently binds the transcription 
factor, Nrf2. Interestingly, FLIP has been shown to 
regulate NF-κB responses in human cells [14]. Thus, one 
explanation for the difference of HO-1 levels in cells with 
FLIPL-targeted knockdown compared to control cells, is 
that removing FLIPL reduces the active NF-κB levels in 
human AML cells, thus removing its negative influence 
on the HO-1 promoter. This would allow HO-1 levels to 
come back to normal non-malignant control levels that are 
observed in ordinary hematopoietic stem cells (HSC). 
We have previously shown that AML cells protect 
themselves  from  TNF-induced  apoptotic  responses  by 
two interconnected mechanisms. The first is the induction 
of  NF-κB-driven  anti-apoptotic  gene  FLIPL. However 
when we remove NF-κB activation using BAY-11-7082, 
a secondary antiapoptotic pathway regulated by the 
transcription factor Nrf2, becomes apparent and drives the 
induction of cytoprotective gene HO-1. In this study we 
show that we do get some TNF-induced apoptosis of AML 
cells when we knockdown FLIPL using siRNA, however 
when we combine the treatment to targeting HO-1 as well, 
we get a markedly increased level of apoptosis in response 
to TNF. This suggests that both FLIPL and HO-1 are two 
genes that when individually targeted have little or no 
effect on apoptosis of AML cells, but targeting these two 
genes in combination would provide a novel mechanism 
that future more successful therapies must employ to 
effectively treat AML.
Our  results  clearly  indicate  that  FLIPL  and  HO-1 
together have a role in controlling TNF-induced apoptotic 
responses in AML cells. It is also clear that knockdown 
of FLIPL induces HO-1 expression in human AML, but 
not corresponding non-malignant control cells The role of 
the other FLIP isoforms, FLIPS and FLIPR, is clearly less 
critical in AML cells in response to TNF. Moreover, the 
fact that we were unable to detect FLIPR protein makes 
it  even  less  of  a  target  molecule  for  future  anti-AML 
therapy. Previously we have shown that HO-1 may play 
an important secondary role in protecting AML cells from 
apoptotic responses, here we cement the concept that 
HO-1 is indeed very important for the survival of AML 
cells and therefore should be targeted with new SACT.
table 1: AML sample information. This table defines the nature of the AML disease including WHO diagnosis and cytogenetics. Percent 
blast denotes the percentage of AML blasts after purification using density gradient centrifugation and in some instances CD34+ positive 
selection.  Previous treatments are as outlined [16].
Number Age Gender WHO diagnosis Cytogenetics % Blasts Previous treatment
AML212 64 male AML with t(8;21)(q22;q22);RUNX1-RUNX1T1 t(8;21) 85 nil
AML217 82 female AML with myelodysplasia related changes deletion 13 85 Hydroxycarbamide
AML301 46 female AML with maturation +4,+8, t(9;22) 70 nil
AML303 40 male Acute promyelocytic leukaemia with 
t(15;17)(q22:q12) PML-RARA
t(15;17) 95 1999 DAT,DAT 
MACE,MiDAC (ref 16)
AML306 78 male AML with myelodysplasia related changes not available 85 nilOncotarget 2010; 1:  359 - 366 365 www.impactjournals.com/oncotarget
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MAterIALs And MetHods
Human research/patient rights
Primary AML cells were obtained under local 
ethical  approval  (LREC  ref  07/H0310/146).  Informed 
consent was obtained from patients and any identifying 
information was anonymised according to the approved 
ethics code of practice. 
Materials
The AML-derived cell lines THP-1 and HL60 were 
obtained from the European Collection of Cell Cultures. 
Anti-human HO-1 antibody was purchased from Assay 
Designs (Ann Arbor, MI).  Anti-human FLIP antibody 
was purchased from Abcam (Cambridge, MA). Control, 
HO-1, FLIPL, FLIPS and FLIPR siRNA were purchased 
from Applied  Biosystems  (Foster  City,  CA). All  other 
reagents  were  obtained  from  Sigma-Aldrich  (St  Louis, 
MO), unless indicated.
cell culture 
For primary cell isolation, heparinized blood was 
collected from volunteers and human peripheral blood 
mononuclear  cells  (PBMCs)  isolated  by  Histopaque 
(Sigma-Aldrich) density gradient centrifugation. PBMCs 
(4 x 106/mL)  were  incubated  in  complete  medium  for 
2 h at 37°C to allow adherence of monocytes. Positive 
selection of human hematopoietic stem cells (HSC) were 
isolated from PBMCs using a CD34 positive selection 
kit (Miltenyi Biotec, Auburn, CA). For all CD34+ and 
primary monocyte experiments at least three different 
donors were used to obtain the results presented in this 
paper. AML samples that were less than 80% blasts and 
expressed CD34, were purified using the CD34 positive 
selection kit. Cell type was confirmed by microscopy and 
flow cytometry.
rnA extraction and real-time Pcr
Total RNA was extracted from 5 x 105 cells using 
the Nucleic acid PrepStation from Applied Biosystems, 
according to the manufacturer’s instructions. Reverse 
transcription was performed using the RNA polymerase 
chain  reaction  (PCR)  core  kit  (Applied  Biosystems). 
Real-time PCR primers were purchased from Invitrogen. 
Relative  quantitative  real-time  PCR  used  SYBR  green 
technology (Roche) on cDNA generated from the reverse 
transcription  of  purified  RNA.  After  preamplification 
(95°C for 2 min), the PCRs were amplified for 45 cycles 
(95°C for 15 s and 60°C for 10 s and 72°C for 10 s) on 
a  LightCycler  480  (Roche).  mRNA  expression  was 
normalized against GAPDH expression using the standard 
curve method.
Western immunoblotting, binding assay and flow 
cytometry
SDS-PAGE and Western analyses were performed 
as described previously [12]. Briefly, whole cell lysates 
were extracted using radioimmunoprecipitation assay 
(RIPA) buffer method. Western blot protein detection was 
by enhanced chemiluminescence (ECL). Flow cytometry 
for measuring apoptosis was performed on an Accuri C6 
flow cytometer (Acurri).
statistical analyses
Student’s t test was performed to assess statistical 
significance from controls. Results with P < 0.05 were 
considered statistically significant (*). Results represent 
the  mean  ±  SEM  of  3  independent  experiments.  For 
Western blotting experiments, data are representative of at 
least 3 separate experiments.
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